Clinical trial NCT05286918 - References

Pulmonary Disease, Chronic Obstructive — Antibiotic Stewardship in AECOPD Through CRP-Guided Management

Citation(s)

•   Al-Jaghbeer MJ, Justo JA, Owens W, Kohn J, Bookstaver PB, Hucks J, Al-Hasan MN
  Risk factors for pneumonia due to beta-lactam-susceptible and beta-lactam-resistant Pseudomonas aeruginosa: a case-case-control study. Infection. 2018 Aug;46(4):487-494. doi: 10.1007/s15010-018-1147-z. Epub 2018 May 11.
•   Brink A, Alsma J, Verdonschot RJCG, Rood PPM, Zietse R, Lingsma HF, Schuit SCE
  Predicting mortality in patients with suspected sepsis at the Emergency Department; A retrospective cohort study comparing qSOFA, SIRS and National Early Warning Score. PLoS One. 2019 Jan 25;14(1):e0211133. doi: 10.1371/journal.pone.0211133. eCollection 2019.
•   Butler CC, Gillespie D, White P, Bates J, Lowe R, Thomas-Jones E, Wootton M, Hood K, Phillips R, Melbye H, Llor C, Cals JWL, Naik G, Kirby N, Gal M, Riga E, Francis NA
  C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. N E
•   Ding X, Wu X, Yu C, Hu S
  Value of C-reactive protein measurement in hospitalized patients with acute exacerbations of chronic obstructive pulmonary disease. Med J Wuhan University. 2006;27(5):660-3.
•   Gillespie D, Francis NA, Carrol ED, Thomas-Jones E, Butler CC, Hood K
  Use of co-primary outcomes for trials of antimicrobial stewardship interventions. Lancet Infect Dis. 2018 Jun;18(6):595-597. doi: 10.1016/S1473-3099(18)30289-5.
•   Goossens H, Ferech M, Vander Stichele R, Elseviers M; ESAC Project Group
  Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005 Feb 12-18;365(9459):579-87.
•   Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, Agusti AA, Vogelmeier CF
  Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2021 Jan 1;203(1):24-36. doi: 10.1164/rccm.202009-3533SO. Review.
•   Hu L, Shi Q, Shi M, Liu R, Wang C
  Diagnostic Value of PCT and CRP for Detecting Serious Bacterial Infections in Patients With Fever of Unknown Origin: A Systematic Review and Meta-analysis. Appl Immunohistochem Mol Morphol. 2017 Sep;25(8):e61-e69. doi: 10.1097/PAI.0000000000000552. Review.
•   Huddy JR, Ni MZ, Barlow J, Majeed A, Hanna GB
  Point-of-care C reactive protein for the diagnosis of lower respiratory tract infection in NHS primary care: a qualitative study of barriers and facilitators to adoption. BMJ Open. 2016 Mar 3;6(3):e009959. doi: 10.1136/bmjopen-2015-009959.
•   Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA
  Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006 Oct 15;174(8):867-74. Epub 2006 Jun 23.
•   Ko FW, Ip M, Chan PK, Ng SS, Chau SS, Hui DS
  A one-year prospective study of infectious etiology in patients hospitalized with acute exacerbations of COPD and concomitant pneumonia. Respir Med. 2008 Aug;102(8):1109-16. doi: 10.1016/j.rmed.2008.03.019. Epub 2008 Jun 24.
•   Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Ståhl E, van der Molen T
  Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res. 2006 Apr 7;7:62.
•   Llor C, Moragas A, Hernández S, Bayona C, Miravitlles M
  Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Oct 15;186(8):716-23. doi: 10.1164/rccm.201206-0996OC. Epub 2012 Aug 23.
•   Mathioudakis AG, Janssens W, Sivapalan P, Singanayagam A, Dransfield MT, Jensen JS, Vestbo J
  Acute exacerbations of chronic obstructive pulmonary disease: in search of diagnostic biomarkers and treatable traits. Thorax. 2020 Jun;75(6):520-527. doi: 10.1136/thoraxjnl-2019-214484. Epub 2020 Mar 26. Review.
•   Mendelson M, Matsoso MP
  The World Health Organization Global Action Plan for antimicrobial resistance. S Afr Med J. 2015 Apr 6;105(5):325. doi: 10.7196/samj.9644.
•   Moher D, Chan AW
  SPIRIT (standard protocol items: recommendations for interventional trials). Guidelines for Reporting Health Research: a user's manual. 2014:56-67.
•   Offen W, Chuang-Stein C, Dmitrienko A, et al
  Multiple co-primary endpoints: medical and statistical solutions: a report from the multiple endpoints expert team of the Pharmaceutical Research and Manufacturers of America. Drug information journal. 2007;41(1):31-46.
•   Pouwels KB, Dolk FCK, Smith DRM, Robotham JV, Smieszek T
  Actual versus 'ideal' antibiotic prescribing for common conditions in English primary care. J Antimicrob Chemother. 2018 Feb 1;73(suppl_2):19-26. doi: 10.1093/jac/dkx502.
•   Sapey E, Stockley RA
  COPD exacerbations . 2: aetiology. Thorax. 2006 Mar;61(3):250-8. Review.
•   Schulz KF, Altman DG, Moher D; CONSORT Group
  CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials. 2010 Mar 24;11:32. doi: 10.1186/1745-6215-11-32.
•   Stolbrink M, Bonnett LJ, Blakey JD
  Antibiotics for COPD exacerbations: does drug or duration matter? A primary care database analysis. BMJ Open Respir Res. 2019 Sep 17;6(1):e000458. doi: 10.1136/bmjresp-2019-000458. eCollection 2019.
•   Strathdee SA, Davies SC, Marcelin JR
  Confronting antimicrobial resistance beyond the COVID-19 pandemic and the 2020 US election. Lancet. 2020 Oct 10;396(10257):1050-1053. doi: 10.1016/S0140-6736(20)32063-8. Epub 2020 Sep 29.
•   Tansarli GS, Mylonakis E
  Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults. Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e00635-18. doi: 10.1128/AAC.00635-18. Print 2018 Sep.
•   von Dach E, Albrich WC, Brunel AS, Prendki V, Cuvelier C, Flury D, Gayet-Ageron A, Huttner B, Kohler P, Lemmenmeier E, McCallin S, Rossel A, Harbarth S, Kaiser L, Bochud PY, Huttner A
  Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial. JAMA. 2020 Jun 2;323(21):2160-2169. doi: 10.1001/jama.2020.6348.

Antibiotic Stewardship Through CRP-guided Antibiotic Treatment for Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

Details for clinical trial NCT05286918